This popped up on a Twitter alert, looks like an interesting long-term play. Writing up more now, but submitting this as it’s popping if anyone wants to hop in.
The company today announced the Food and Drug Administration approved Igalmi, a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder in adults. The therapy is expected to launch in the U.S. in the second quarter of this year.
With this, BoA gave it an $80 PT, and Jeffries a $125 PT. It has a current 52-week high of $39, so with any of these numbers in mind, it’s trading fairly well below that.
I scalped a June call this morning, but re-entered with 2023 25c after seeing the Jeffries update.
Adding 500 shares in an account that I don’t need to touch for a while.